ReviewOncogene2003
Survivin, versatile modulation of cell division and apoptosis in cancer.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 329 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
329 citing papers in PubMed, 2 syntheses or guidelines pooled it, 900 citations in OpenAlex.
- The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis.BMC cancer · 2021Pooled it
- Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.Cancer immunology, immunotherapy : CII · 2014Trial
- Overcoming Resistance: Targeting Survivin-Driven Apoptotic Resistance Restores Irinotecan Sensitivity inCancers · 2026Article
- Survivin-Targeting Antisense Oligonucleotides in Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- Lnc00892 enhances cisplatin sensitivity by inducing apoptosis through the BTAF1/MDM2/STAT5B/XIAP axis in bladder cancer cells.Biology direct · 2026Article
- Marine trichodermamide B inhibits prostate cancer progression via catalase inhibition-induced apoptosis.Cell communication and signaling : CCS · 2026Article
- Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics.International journal of molecular sciences · 2026Article
- Xiao Chai Hu Tang-derived decoction (Tung-Yi Fang) suppresses triple negative breast cancer cellsFrontiers in pharmacology · 2026Article
- Cicer arietinum extract as antitumor and protective agent against Ehrlich Solid Carcinoma-bearing mice.BMC complementary medicine and therapies · 2025Article
- Identification of SUMOylation modifiers involved in lung adenocarcinoma progression and Osimertinib resistance by integrated bioinformatics analysis.Scientific reports · 2025Article
- Effect of human survivin-2B-specific cytotoxic CD8+ T lymphocytes on CD44+/- HSC-2 and HSC-3 oral cancer cells.European journal of oral sciences · 2025Article
- Integrative single-cell and bulk transcriptomic analyses identify a robust four-gene signature for risk stratification in neuroblastoma.Translational cancer research · 2025Article
- Cationic Metal-Organic Layer Delivers siRNAs to Overcome Radioresistance and Potentiate Cancer Radiotherapy.Angewandte Chemie (International ed. in English) · 2025Article
- Bivalent chromatin accommodates survivin and BRG1/SWI complex to activate DNA damage response in CD4Cell communication and signaling : CCS · 2024Article
- Article
- Peptide-Based Turn-On Fluorescent Probes for Highly Specific Detection of Survivin Protein in the Cancer Cells.Chemical & biomedical imaging · 2024Article
- The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.International journal of molecular sciences · 2024Article
- Juglone-ascorbate treatment enhances reactive oxygen species mediated mitochondrial apoptosis in pancreatic cancer.Molecular biology reports · 2024Article
- Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer.Pharmaceutics · 2024Article
269 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Survivin is a member of the inhibitor of apoptosis (IAP) gene family that has attracted attention from several viewpoints of basic and translational research. Its cell cycle-regulated expression at mitosis and association with the mitotic apparatus have been of interest to cell biologists studying faithful segregation of sister chromatids and timely separation of daughter cells. Investigators interested in mechanisms of apoptosis have found survivin an evolving challenge: while survivin inhibits apoptosis in vitro and in vivo, this pathway may be more selective as compared to cytoprotection mediated by other IAPs. Finally, basic and translational researchers in cancer biology have converged on survivin as a pivotal cancer gene, not simply for its sharp expression in tumors and not in normal tissues, but also for the potential exploitation of this pathway in cancer diagnosis and therapy. The objective of the present contribution is to line up current evidence and emerging concepts on the multifaceted functions of survivin in cell death and cell division, and how this pathway is being pursued for novel cancer therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.